Anthony Mato MD, MSCE

Anthony Mato, MD, MSCE, is Director of the Chronic Lymphocytic Leukemia (CLL) Program at Memorial Sloan Kettering Cancer Center (MSKCC).

Dr. Mato earned his medical degree from SUNY Buffalo and a Master's of Science in clinical epidemiology from the University of Pennsylvania School of Medicine. He completed his residency and fellowship at the Hospital of the University of Pennsylvania and is board-certified in internal medicine with subspecialties in hematology and medical oncology.

Dr. Mato specializes in the treatment of CLL and lymphoproliferative disorders. In his current role, he oversees a team of experts who are dedicated to all aspects of diagnosing and treating CLL. He and his team develop the best treatment plans tailored to each patient's unique situation by providing access to and safely administering the newest therapies through clinical trials Their mission is to provide patients with state-of-the-art monitoring and treatments like immunotherapy through clinical research and expertise.

A well-published scholar, Dr. Mato regularly contributes articles to peer-reviewed journals, including Blood, British Journal of Hematology, Annals of Oncology, Heamatologica, Lancet Oncology, and American Journal of Hematology. He also holds professional memberships with the American Society of Clinical Oncology, the American Society of Hematology, and the American College of Physician Executives. Additionally, Dr. Mato serves on the medical advisory board for the CLL Society, a patient-centric, physician-curated nonprofit organization focused on patient education and support.